top of page


Cell and Gene Therapy Updates
June 3rd week, 2025 Regulatory Updates 🎯 Senti Biosciences received an ODD from the US FDA for SENTI-202 (off-the-shelf CD33 and/or...
Oncofocus Team
Jun 252 min read


Cell and Gene Therapy Updates
June 2nd week, 2025 ⭐ Deals & Collaborations 🤝Neowise Biotechnology granted BeOne Medicines rights to one of its proprietary...
Oncofocus Team
Jun 232 min read


Cell and Gene Therapy Updates
May 5th & June 1st Week ⭐ Regulatory Updates 🎯 China’s NMPA granted Priority Review to CARsgen Therapeutics ’ satri-cel (CT041; an...
Oncofocus Team
Jun 232 min read


Cell and Gene Therapy Updates
May 3rd Week, 2025 ⭐ Regulatory Update 🎯 The US FDA granted the RMAT designation to BrainChild Bio ’s BCB-276 (an autologous, B7-H3...
Oncofocus Team
Jun 232 min read


Cell and Gene Therapy Updates
May 1st & 2nd Week, 2025 ⭐ Deals & Collaborations 🤝 NKure Therapeutics and CRISPR Therapeutics partnered to co-develop CRISPR’s...
Oncofocus Team
Jun 232 min read


Cell and Gene Therapy Updates
April 3rd & 4th, 2025 Regulatory Updates 🎯 The UK MHRA granted conditional marketing authorization for Autolus Therapeutics ’...
Oncofocus Team
Jun 202 min read


Cell and Gene Therapy Updates
April 2nd April, 2025 ⭐ Regulatory Events 🎯 The US FDA cleared an IND application of CERo Therapeutics, Inc. ’s CER-1236 (anti-Tim-4L...
Oncofocus Team
Jun 201 min read


Cell and Gene Therapy Updates
March 3rd Week, 2025 Regulatory Events 🎯 The European commission granted approval to Bristol Myers Squibb ’ Breyanzi (lisocabtagene...
Oncofocus Team
Jun 202 min read


Cell and Gene Therapy Updates
March 1st Week, 2025 ⭐ Regulatory Events 🎯 China’s NMPA granted Breakthrough Therapy Designation (BTD) to CARsgen Therapeutics ’...
Oncofocus Team
Jun 201 min read


Cell and Gene Therapy Updates
February 4th Week, 2025 📝 The US FDA granted RMAT designation for ImmunityBio ’s Anktiva (n ogapendekin alfa inbakicept; IL-15...
Oncofocus Team
Jun 201 min read


Cell and Gene Therapy Updates
February 3rd Week, 2025 📝 BMS’ Breyanzi (liso-cel; an autologous, anti-CD19 CAR-T) received NICE recommendation as an option for...
Oncofocus Team
Jun 201 min read


Cell and Gene Therapy Updates
February 2nd Week, 2025 📝 BMS’ Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel; an autologous, anti-CD19 CAR-T) met...
Oncofocus Team
Jun 202 min read
bottom of page